Phase 3 Clinical Trials With Primary Completion Dates in October 2025
This is a list of Phase 3 trials with primary completion dates in October 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2025-10-01 | Phase 3 | NCT06173531 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome |
| IBRX | ImmunityBio, Inc. | 2025-10-01 | Phase 3 | NCT03520686 | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. |
| NPPNY | Nippon Shinyaku Co., Ltd. | 2025-10-01 | Phase 3 | NCT04768062 | Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) |
| REGMF | RemeGen Co., Ltd. | 2025-10-01 | Phase 3 | NCT05799287 | A Study of Telitacicept in Patients with Primary Immunoglobulin A（IgA） Nephropathy |
| SOLTF | Nxera Pharma Co., Ltd. | 2025-10-01 | Phase 3 | NCT07028697 | A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder |
| VTGN | Vistagen Therapeutics, Inc. | 2025-10-01 | Phase 3 | NCT06358651 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) |